Sana Biotechnology, Inc. (SANA)
NASDAQ: SANA · IEX Real-Time Price · USD
9.78
+0.15 (1.56%)
At close: May 2, 2024, 4:00 PM
10.07
+0.29 (2.97%)
After-hours: May 2, 2024, 5:58 PM EDT
Sana Biotechnology Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
328
Market Cap
2.16B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amphastar Pharmaceuticals | 644.40M |
Ginkgo Bioworks Holdings | 251.46M |
RxSight | 89.08M |
Kymera Therapeutics | 78.59M |
Intellia Therapeutics | 36.28M |
NewAmsterdam Pharma Company | 15.66M |
Avidity Biosciences | 9.56M |
Keros Therapeutics | 151.00K |
SANA News
- 10 days ago - Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX - Invezz
- 2 months ago - Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP - GlobeNewsWire
- 2 months ago - Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 3 months ago - Sana Biotechnology Announces Pricing of Upsized Public Offering - GlobeNewsWire
- 3 months ago - Sana Biotechnology Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies - GlobeNewsWire